Evolving strategies: future treatment of glioblastoma

References

• Louis DN, Ohgaki H, Wiestler OD et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol.114, 97–109 (2007).
   PubMed Web of Science ®Google Scholar
• Wen PY, Kesari S. Malignant gliomas in adults. N. Engl. J. Med.359, 492–507 (2008).
   PubMed Web of Science ®Google Scholar
• Stupp R, Dietrich PY, Ostermann KS et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J. Clin. Oncol.20, 1375–1382 (2002).
   PubMed Web of Science ®Google Scholar
• Miletic H, Niclou SP, Johansson M, Bjerkvig R. Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms. Expert Opin. Ther. Targets13, 455–468 (2009).
   PubMed Web of Science ®Google Scholar
• Combs SE, Gutwein S, Thilmann C, Huber P, Debus J, Schulz-Ertner D. Stereotactically guided fractionated re-irradiation in recurrent glioblastoma multiforme. J. Neurooncol.74, 167–171 (2005).
   PubMed Web of Science ®Google Scholar
• Maity A, Pore N, Lee J, Solomon D, O’Rourke DM. Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3´-kinase and distinct from that induced by hypoxia. Cancer Res.60, 5879–5886 (2000).
   PubMed Web of Science ®Google Scholar
• Brandes AA, Tosoni A, Franceschi E et al. Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation with MGMT promoter methylation status. J. Clin. Oncol.27, 1275–1279 (2009).
   PubMed Web of Science ®Google Scholar
• Zuniga RM, Torcuator R, Jain R et al. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J. Neurooncol.91, 329–336 (2009).
   PubMed Web of Science ®Google Scholar
• Gorlia T, van den Bent MJ, Hegi ME et al. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981–22981/CE.3. Lancet Oncol.9, 29–38 (2008).
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med.352, 987–996 (2005).
   PubMed Web of Science ®Google Scholar
• Hegi ME, Diserens AC, Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med.352, 997–1003 (2005).
   PubMed Web of Science ®Google Scholar
• Rosell R, de Las PR, Balana C et al. Translational research in glioblastoma multi-forme: molecular criteria for patient selection. Future Oncol.4, 219–228 (2008).
   PubMed Web of Science ®Google Scholar
• Westphal M, Hilt DC, Bortey E et al. A Phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro. Oncol.5, 79–88 (2003).
   PubMed Web of Science ®Google Scholar
• Spiegel BM, Esrailian E, Laine L, Chamberlain MC. Clinical impact of adjuvant chemotherapy in glioblastoma multiforme: a meta-analysis. CNS Drugs21, 775–787 (2007).
   PubMed Web of Science ®Google Scholar
• Norden AD, Young GS, Setayesh K et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology70, 779–787 (2008).
   PubMed Web of Science ®Google Scholar
• Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto Phase II clinical trials. J. Clin. Oncol.17, 2572–2578 (1999).
   PubMed Web of Science ®Google Scholar
• Ballman KV, Buckner JC, Brown PD et al. The relationship between six-month progression-free survival and 12-month overall survival end points for Phase II trials in patients with glioblastoma multiforme. Neuro. Oncol.9, 29–38 (2007).
   PubMed Web of Science ®Google Scholar
• Lamborn KR, Yung WK, Chang SM et al. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro. Oncol.10, 162–170 (2008).
   PubMed Web of Science ®Google Scholar
• Idbaih A, Ducray F, Sierra DR, Hoang-Xuan K, Delattre JY. Therapeutic application of noncytotoxic molecular targeted therapy in gliomas: growth factor receptors and angiogenesis inhibitors. Oncologist13, 978–992 (2008).
   PubMedGoogle Scholar
• Kreisl TN, Kim L, Moore K et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J. Clin. Oncol.27, 740–745 (2009).
   PubMed Web of Science ®Google Scholar
• Friedman HS, Prados MD, Wen PY et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol.27, 4733–4740 (2009).
   PubMed Web of Science ®Google Scholar
• Sul J, Panageas KS, Lassman AB et al. A randomized Phase II trial of concurrent temozolomide (TMZ) and radiotherapy (RT) followed by dose dense compared to metronomic TMZ and maintenance cis-retinoic acid for patients with newly diagnosed glioblastoma multiforme (GBM). J. Clin. Oncol.25(S18), Abstract 2031 (2007).
   Google Scholar
• Alnaami IM, Mehta V, Gourishnkar S, Senthilselvan A. Evaluation of concomitant temozolomide and radiotherapy treatment in patients with glioblastoma multiforme in two Canadian tertiary care centers. Neuro. Oncol.11(5), 583 (2009).
   Google Scholar
• Wick A, Pascher C, Wick W et al. Rechallenge with temozolomide in patients with recurrent gliomas. J. Neurol.256, 734–741 (2009).
   PubMed Web of Science ®Google Scholar
• Perry JR, Rizek P, Cashman R, Morrison M, Morrison T. Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the ‘rescue’ approach. Cancer113, 2152–2157 (2008).
   PubMed Web of Science ®Google Scholar
• Brada M, Stenning S, Gabe R et al. Temozolomide versus procarbazine, lomustine and vincristine in recurrent high-grade glioma. J. Clin. Oncol.28, 4601–4608 (2010).
   PubMed Web of Science ®Google Scholar
• Pennell NA, Lynch TJ Jr. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC. Oncologist14, 399–411 (2009).
   PubMed Web of Science ®Google Scholar
• Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J. Mol. Med.77, 527–543 (1999).
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat. Med.9, 669–676 (2003).
   PubMed Web of Science ®Google Scholar
• Goudar RK, Vlahovic G. Hypoxia, angiogenesis, and lung cancer. Curr. Oncol. Rep.10, 277–282 (2008).
   PubMed Web of Science ®Google Scholar
• Morabito A, De Maio E, Di Maio M, Normanno N, Perrone F. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist11, 753–764 (2006).
   PubMed Web of Science ®Google Scholar
• Kowanetz M, Ferrara N. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin. Cancer Res.12, 5018–5022 (2006).
   PubMed Web of Science ®Google Scholar
• Kiselyov A, Balakin KV, Tkachenko SE. VEGF/VEGFR signalling as a target for inhibiting angiogenesis. Expert Opin. Investig. Drugs16, 83–107 (2007).
   PubMed Web of Science ®Google Scholar
• Schneider BP, Sledge GW Jr. Drug insight: VEGF as a therapeutic target for breast cancer. Nat. Clin. Pract. Oncol.4, 181–189 (2007).
   PubMedGoogle Scholar
• Fontanini G, Vignati S, Boldrini L et al. Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin. Cancer Res.3, 861–865 (1997).
   PubMed Web of Science ®Google Scholar
• Fontanini G, Faviana P, Lucchi M et al. A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma. Br. J. Cancer86, 558–563 (2002).
   PubMed Web of Science ®Google Scholar
• Greten TF, Korangy F, Manns MP, Malek NP. Molecular therapy for the treatment of hepatocellular carcinoma. Br. J. Cancer100, 19–23 (2009).
   PubMed Web of Science ®Google Scholar
• Skelton MR, O’Neil B. Targeted therapies for hepatocellular carcinoma. Clin. Adv. Hematol. Oncol.6, 209–218 (2008).
   PubMedGoogle Scholar
• Shahi PK, Lovelle AS, Manga GP. Tumoral angiogenesis and breast cancer. Clin. Transl. Oncol.11, 138–142 (2009).
   PubMedGoogle Scholar
• Lennard CM, Patel A, Wilson J et al. Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer. Surgery129, 552–558 (2001).
   PubMed Web of Science ®Google Scholar
• Klein M, Picard E, Vignaud JM et al. Vascular endothelial growth factor gene and protein: strong expression in thyroiditis and thyroid carcinoma. J. Endocrinol.161, 41–49 (1999).
   PubMed Web of Science ®Google Scholar
• Oka N, Soeda A, Inagaki A et al. VEGF promotes tumorigenesis and angiogenesis of human glioblastoma stem cells. Biochem. Biophys. Res. Commun.360, 553–559 (2007).
   PubMed Web of Science ®Google Scholar
• Bahleda R, Soria J, Harbison C et al. Tumor regression and pharmacodynamic (PD) biomarker validation in non-small cell lung cancer (NSCLC) patients treated with the ErbB/VEGFR inhibitor BMS-690514. J. Clin. Oncol.27(S15), Abstract 8098 (2009).
   Google Scholar
• Nam DH, Park K, Suh YL, Kim JH. Expression of VEGF and brain specific angiogenesis inhibitor-1 in glioblastoma: prognostic significance. Oncol. Rep.11, 863–869 (2004).
   PubMed Web of Science ®Google Scholar
• Kong DS, Song SY, Kim DH et al. Prognostic significance of c-Met expression in glioblastomas. Cancer115, 140–148 (2009).
   PubMed Web of Science ®Google Scholar
• Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat. Rev. Drug Discov.7, 504–516 (2008).
   PubMed Web of Science ®Google Scholar
• Natale RB, Bodkin D, Govindan R et al. Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized Phase II study. J. Clin. Oncol.27, 2523–2529 (2009).
   PubMed Web of Science ®Google Scholar
• Herbst R, Sun Y, Korfee S et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): a randomized, double-blind Phase III trial (ZODIAC). J. Clin. Oncol.27(18 Suppl.), Abstract CRA8003 (2009).
   Google Scholar
• Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med.359, 378–390 (2008).
   PubMed Web of Science ®Google Scholar
• Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer8, 592–603 (2008).
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature407, 249–257 (2000).
   PubMed Web of Science ®Google Scholar
• Folkman J. What is the evidence that tumors are angiogenesis dependent? J. Natl Cancer Inst.82, 4–6 (1990).
   PubMed Web of Science ®Google Scholar
• Horn L, Sandler A. Angiogenesis in the treatment of non-small cell lung cancer. Proc. Am. Thorac. Soc.6, 206–217 (2009).
   PubMedGoogle Scholar
• Sathornsumetee S, Rich JN. Antiangiogenic therapy in malignant glioma: promise and challenge. Curr. Pharm. Des.13, 3545–3558 (2007).
   PubMed Web of Science ®Google Scholar
• Sathornsumetee S, Reardon DA, Desjardins A, Quinn JA, Vredenburgh JJ, Rich JN. Molecularly targeted therapy for malignant glioma. Cancer110, 13–24 (2007).
   PubMed Web of Science ®Google Scholar
• Roberts WG, Delaat J, Nagane M, Huang S, Cavenee WK, Palade GE. Host microvasculature influence on tumor vascular morphology and endothelial gene expression. Am. J. Pathol.153, 1239–1248 (1998).
   PubMed Web of Science ®Google Scholar
• Takano S, Yoshii Y, Kondo S et al. Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. Cancer Res.56, 2185–2190 (1996).
   PubMed Web of Science ®Google Scholar
• Calabrese C, Poppleton H, Kocak M. A perivascular niche for brain tumor stem cells. Cancer Cell.11, 69–82 (2007).
   PubMed Web of Science ®Google Scholar
• Peles E, Lidar Z, Simon AJ, Grossman R, Nass D, Ram Z. Angiogenic factors in the cerebrospinal fluid of patients with astrocytic brain tumors. Neurosurgery55, 562–567 (2004).
   PubMed Web of Science ®Google Scholar
• Quesada AR, Medina MA, Alba E. Playing only one instrument may be not enough: limitations and future of the antiangiogenic treatment of cancer. Bioessays29, 1159–1168 (2007).
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber HP. The role of vascular endothelial growth factor in angiogenesis. Acta Haematol.106, 148–156 (2001).
   PubMed Web of Science ®Google Scholar
• Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr. Rev.18, 4–25 (1997).
   PubMed Web of Science ®Google Scholar
• Cao Y, Liu Q. Therapeutic targets of multiple angiogenic factors for the treatment of cancer and metastasis. Adv. Cancer Res.97, 203–224 (2007).
   PubMed Web of Science ®Google Scholar
• Goldfarb M. The fibroblast growth factor family. Cell Growth Differ.1, 439–445 (1990).
   PubMedGoogle Scholar
• Prat A, Casado E, Cortes J. New approaches in angiogenic targeting for colorectal cancer. World J. Gastroenterol.13, 5857–5866 (2007).
   PubMed Web of Science ®Google Scholar
• Tortora G, Ciardiello F, Gasparini G. Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications. Nat. Clin. Pract. Oncol.5, 521–530 (2008).
   PubMedGoogle Scholar
• Herbst RS, Johnson DH, Mininberg E et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J. Clin. Oncol.23, 2544–2555 (2005).
   PubMed Web of Science ®Google Scholar
• Tabernero J. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol. Cancer Res.5, 203–220 (2007).
   PubMed Web of Science ®Google Scholar
• Ciardiello F, Troiani T, Bianco R et al. Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy. Ann. Oncol.17(Suppl. 7), vii109–vii114 (2006).
   PubMed Web of Science ®Google Scholar
• You WK, Falcon B, Hashizume H et al. Exaggerated regression of blood vessels, hypoxia, and apoptosis in tumors after c-Met and VEGFR inhibition. J. Clin. Invest. (2011) (In press).
   Google Scholar
• Li Y, Guessous F, DiPierro C. Interactions between PTEN and the c-Met pathway in glioblastoma and implications for therapy. Mol. Cancer Ther.8, 376–385 (2009).
   PubMed Web of Science ®Google Scholar
• Martens T, Schmidt NO, Eckerich C et al. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin. Cancer Res.12, 6144–6152 (2006).
   PubMed Web of Science ®Google Scholar
• Chu SH, Feng DF, Zhang H et al. c-Met-targeted RNA interference inhibits growth and metastasis of glioma U251 cells in vitro. J. Neurooncol.93, 183–189 (2009).
   PubMedGoogle Scholar
• Santarpia L, Ye L, Gagel RF. Beyond RET: potential therapeutic approaches for advanced and metastatic medullary thyroid carcinoma. J. Intern. Med.266, 99–113 (2009).
   PubMedGoogle Scholar
• Jeffers M, Fiscella M, Webb CP et al. The mutationally activated MET receptor mediates motility and metastasis. Proc. Natl Acad. Sci. USA95, 14417–14422 (1998).
   PubMed Web of Science ®Google Scholar
• Giordano S, Bardelli A, Zhen Z, Menard S, Ponzetto C, Comoglio PM. A point mutation in the MET oncogene abrogates metastasis without affecting transformation. Proc. Natl Acad. Sci. USA94, 13868–13872 (1997).
   PubMedGoogle Scholar
• Schmidt NO, Westphal M, Hagel C et al. Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis. Int. J. Cancer84, 10–18 (1999).
   PubMed Web of Science ®Google Scholar
• Bean J, Brennan C, Shih JY et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc. Natl Acad. Sci. USA104, 20932–20937 (2007).
   PubMed Web of Science ®Google Scholar
• Chu SH, Zhu ZA, Yuan XH, Li ZQ, Jiang PC. In vitro and in vivo potentiating the cytotoxic effect of radiation on human U251 gliomas by the c-Met antisense oligodeoxynucleotides. J. Neurooncol.80, 143–149 (2006).
   PubMedGoogle Scholar
• Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell15, 232–239 (2009).
   PubMed Web of Science ®Google Scholar
• Loges S, Mazzone M, Hohensinner P, Carmeliet P. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell15, 167–170 (2009).
   PubMed Web of Science ®Google Scholar
• Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell3, 347–361 (2003).
   PubMed Web of Science ®Google Scholar
• Jain RK, Duda DG, Willett CG et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat. Rev. Clin. Oncol.6, 327–338 (2009).
   PubMed Web of Science ®Google Scholar
• Paez-Ribes M, Allen E, Hudock J et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell15, 220–231 (2009).
   PubMed Web of Science ®Google Scholar
• Kamoun WS, Ley CD, Farrar CT et al. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J. Clin. Oncol.27, 2542–2552 (2009).
   PubMed Web of Science ®Google Scholar
• Pope WB, Xia Q, Paton VE et al. Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab. Neurology76, 432–437 (2011).
   PubMed Web of Science ®Google Scholar
• Wick A, Dorner N, Schafer N et al. Bevacizumab does not increase the risk of remote relapse in malignant glioma. Ann. Neurol. (2011) (In press).
   PubMedGoogle Scholar
• Chamberlain MC. Radiographic patterns of relapse in glioblastoma. J. Neurooncol.101(2), 319–323 (2011).
   PubMed Web of Science ®Google Scholar
• Banerjee S, Dowsett M, Ashworth A, Martin LA. Mechanisms of disease: angiogenesis and the management of breast cancer. Nat. Clin. Pract. Oncol.4(9), 536–550 (2007).
   PubMedGoogle Scholar
• Fox SB, Generali DG, Harris AL. Breast tumour angiogenesis. Breast Cancer Res.9, 216 (2007).
   PubMed Web of Science ®Google Scholar
• Grose R, Dickson C. Fibroblast growth factor signaling in tumorigenesis. Cytokine Growth Factor Rev.16, 179–186 (2005).
   PubMed Web of Science ®Google Scholar
• van Linde ME, Verhoeff JJC, Stalpers LJA, Reijneveld JC, Richel DJ, Van Furth WR. Feasibility of combined treatment with bevacizumab radiotherapy and temozolomide in resectable and unresectable newly diagnosed glioblastoma multiforme. Neuro. Oncol.11(5), 563–699 (2009).
   Google Scholar
• Hofland KF, Poulsen HS, Sorensen MP et al. First-line therapy with bevacizumab and irinotecan versus bevacizumab and temozolomide and delayed concomitant radiotherapy in newly diagnosed primary glioblastoma multiforme: early results from a randomized Phase II study. Neuro. Oncol.11(5), 620 (2009).
   Google Scholar
• Lai A, Nghiemphu P, Pope W, et al. Phase II study of bevacizumab plus temozolomide during and after radiotherapy for patients with newly diagnosed glioblastoma multiforme. J. Clin. Oncol.29(2), 142–148 (2011).
   PubMed Web of Science ®Google Scholar
• Desjardins A, Reardon DA, Peters KB et al. Bevacizumab (BV) in combination to temozolomide (TMZ) and radiation therapy (RT) followed by BV, TMZ, and irinotecan (CPT-11) for newly diagnosed glioblastoma multiforme (GBM): a Phase 2 trial. Neuro. Oncol.11(5), 634 (2009).
   Google Scholar
• Gruber ML, Raza S, Gruber D, Narayana A. Bevacizumab in combination with radiotherapy plus concomitant and adjuvant temozolomide for newly diagnosed glioblastoma: update progression-free survival, overall survival, and toxicity. J. Clin. Oncol.27(15S), Abstract 2017 (2009).
   Google Scholar
• Peters K, Desjardins A, Reardon DA et al. Temozolomide (TMZ) and bevacizumab (BV) as initial treatment for unresectable or multifocal glioblastoma multiforme (GBM). J. Clin. Oncol.27(Suppl.), e13025 (2009).
   Google Scholar
• Chinot O, de La Motte Rouge T, Zeaiter A et al. Preclinical and clinical rationale for a Phase III trial of bevacizumab combined with the current standard of care in patients with newly diagnosed glioblastoma multiforme. Neuro. Oncol.11(5), 628 (2009).
   Google Scholar
• Reardon DA, Fink KL, Mikkelsen T et al. Randomized Phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J. Clin. Oncol.26, 5610–5617 (2008).
   PubMed Web of Science ®Google Scholar
• Stupp R, Goldbrunner R, Neyns B et al. Phase I/IIa trial of cilengitide (EMD121974) and temozolomide with concomitant radiotherapy, followed by temozolomide and cilengitide maintenance therapy in patients with newly diagnosed glioblastoma. J. Clin. Oncol.25(18S), Abstract 2000 (2007).
   Google Scholar
• Lamar RE, Spigel DR, Burris HA et al. Phase II trial of radiation therapy/temozolomide followed by temozolomide/sorafenib in the first-line treatment of glioblastoma multiforme (GBM). J. Clin. Oncol.27(15S), Abstract 2018 (2009).
   Google Scholar
• Brown PD, Krishnan S, Sarkaria JN et al. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J. Clin. Oncol.26, 5603–5609 (2008).
   PubMed Web of Science ®Google Scholar
• Prados MD, Chang SM, Butowski N et al. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J. Clin. Oncol.27, 579–584 (2009).
   PubMed Web of Science ®Google Scholar
• Heimberger AB, Archer GE, Mitchell DA et al. Epidermal growth factor receptor variant II (EGFRvIII) vaccine (CDX-110) in GBM. J. Clin. Oncol.27(15S), Abstract 2021 (2009).
   Google Scholar
• Sampson JH, heimberger AB, Archer GE et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J. Clin. Oncol.31, 4722–4729 (2010).
   Google Scholar
• Rosenfeld MR, Chamberlain M, Grossman SA et al. A Phase II study of chemoradiation followed by adjuvant temozolomide and poly-ICLC in patients with newly diagnosed glioblastoma: 12- and 18-month survival data (NABTT 0501) [abstract]. J. Clin. Oncol.27(15S), Abstract 2002 (2009).
   PubMedGoogle Scholar
• Grossman SA, Ye X, Chamberlain M et al. Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter Phase II trial. J. Clin. Oncol.27, 4155–4161 (2009).
   PubMed Web of Science ®Google Scholar
• Takano T, Lin JH, Arcuino G, Gao Q, Yang J, Nedergaard M. Glutamate release promotes growth of malignant gliomas. Nat. Med.7, 1010–1015 (2001).
   PubMed Web of Science ®Google Scholar
• Yoshida Y, Tsuzuki K, Ishiuchi S, Ozawa S. Serum-dependence of AMPA receptor-mediated proliferation in glioma cells. Pathol. Int.56, 262–271 (2006).
   PubMedGoogle Scholar
• Lyons SA, Chung WJ, Weaver AK, Ogunrinu T, Sontheimer H. Autocrine glutamate signaling promotes glioma cell invasion. Cancer Res.67, 9463–9471 (2007).
   PubMedGoogle Scholar
• Hurwitz HI, Fehrenbacher L, Hainsworth JD et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J. Clin. Oncol.23, 3502–3508 (2005).
   PubMed Web of Science ®Google Scholar
• Kerr C. Bevacizumab and chemotherapy improves survival in NSCLC. Lancet Oncol.6, 266 (2005).
   PubMedGoogle Scholar
• Vredenburgh JJ, Desjardins A, Herndon JE et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J. Clin. Oncol.25, 4722–4729 (2007).
   PubMed Web of Science ®Google Scholar
• Gilbert MR, Wang M, Aldape K et al. RTOG 0625: a Phase II study of bevacizumab with irinotecan in recurrent glioblastoma (GBM). J. Clin. Oncol.27(15S), Abstract 2011 (2009).
   Google Scholar
• Stankewitz S, Dresemann G. Addition of continuous low dose temozolomide to bevacizumab plus irinotecan after bevacizumab plus irinotecan failure in heavily pretreated glioblastoma multiforme (GBM). J. Clin. Oncol.27(Suppl.), e13015 (2009).
   Google Scholar
• Batchelor TT, Sorensen AG, di Tomaso E et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell11, 83–95 (2007).
   PubMed Web of Science ®Google Scholar
• Sennino B. Inhibition of tumor invasiveness by c-Met/VEGFR blockade. Presented at: Gordon Research Conference: Angiogenesis, RI, USA, 2–7 August 2009.
   Google Scholar
• de Groot JF, Prados M, Urquhart T et al. A Phase II study of XL184 in patients (pts) with progressive glioblastoma multiforme (GBM) in first or second relapse. J. Clin. Oncol.27(15S), Abstract 2047 (2009).
   PubMedGoogle Scholar
• Wen PY, Cloughesy T, Kuhn J et al. Phase I/II study of sorafenib and temsiroliums for patients with recurrent glioblastoma (GBM) (NABTC 05–02) [abstract]. J. Clin. Oncol.27(15S), Abstract 2006 (2009).
   Google Scholar
• Chaskis C, Dujardin M, Michotte A, Neyns B. Evaluation of the early antiangiogenic activity of sunitinib malate by perfusion of CBF and CBV values from DSC-based perfusion in recurrent glioblastoma. Neuro. Oncol.10, 1062 (2008).
   Google Scholar
• Neyns B, Chaskis C, Dujardin M et al. Phase II trial of sunitinib malate in patients with temozolomide refractory recurrent high-grade glioma. J. Clin. Oncol.27(15S), Abstract 2038 (2009).
   Google Scholar
• van den Bent MJ, Brandes AA, Rampling R et al. Randomized Phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J. Clin. Oncol.27, 1268–1274 (2009).
   PubMed Web of Science ®Google Scholar
• Chang SM, Kuhn J, Lamborn K et al. Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas (MG) (NABTC 04–02). J. Clin. Oncol.27(15S), Abstract 2004 (2009).
   Google Scholar
• Wick W, Puduvalli VK, Chamberlain MC et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J. Clin. Oncol.28, 1168–1174 (2010).
   PubMed Web of Science ®Google Scholar
• Wick W, Puduvalli VK, Chamberlain M et al. Enzastaurin (ENZ) versus lomustine (CCNU) in the treatment of recurrent, intracranial glioblastoma (GBM): a Phase III study. Neuro. Oncol.10, Abstract 022 (2008).
   PubMedGoogle Scholar
• Kerbel RS. Tumor angiogenesis. N. Engl. J. Med.358, 2039–2049 (2008).
   PubMed Web of Science ®Google Scholar
• Fojo T. Commentary: novel therapies for cancer: why dirty might be better. Oncologist13, 277–283 (2008).
   PubMed Web of Science ®Google Scholar
• Nabors LB, Mikkelsen T, Batchelor T et al. NABTT 0306: a randomized Phase II trial of EMD 121974 in conjunction with concomitant and adjuvant temozolomide with radiation therapy in patients with newly diagnosed glioblastoma multiforme (GBM). J. Clin. Oncol.27(15S), Abstract 2001 (2009).
   Google Scholar
• Nabors LB, Fiveash JB, Markert JM et al. A Phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma. Arch. Neurol.67, 313–319 (2010).
   PubMedGoogle Scholar